Abstract 1654P
Background
CTCs have been extensively studied in different neoplasms. There are several techniques for their identification, however, it is not clear which is the most effective. In pancreatic cancer (PC) their significance in different stages of the disease and correlation with tumor markers are poorly understood.
Methods
Prospective, observational, cohort study in two Spanish centers. We analyzed CTCs at day 0 (before chemotherapy). Isolation was carried out with Isoflux technology, combining cell separation by immunomagnetic particles (positive selection) with a microfluidic system. Four different markers were used, including two mesenchymal markers, EpCAM and EGFR. The count of CTCs was done in a confocal microscope using the iMSRC (intelligent Matrix Screen Remote Control). Primary endpoint was the correlation of CTCs with overall survival (OS). Secondary endpoints: correlation between CTCs with Ca19.9/CEA values and the difference in the median value of CTCs in metastatic compared to locally advanced disease were secondary endpoints.
Results
Sixty-three patients were analyzed. Clinical characteristics: (Table) Median follow up was 11.6 months. Median value of CTC-0 was 343 (range 33 - 6259) for metastatic patients while it was 436 (81 - 1082) for locally advanced patients (p = 0.380). Correlation coefficient for Ca 19.9 was 0.03 (p = 0.824); CEA correlation coefficient was 0.121 (p = 0.366). Kaplan-Meier analysis showed an estimated median OS of 9.9 months for > 500 CTCs (95% confident interval [95% CI] 8.1 – 11.6) vs 14.7 (95% confident interval [95% CI] 6.7 – 22.6) for < 500 CTCs (p = 0.021).
Table: 1654P
Clinical characteristics | Results |
Median age (range) - yr | 65 (45 – 85) |
Sex – no. (%) Male Female | 35 (55.67) 28 (44.4) |
Stage at diagnosis – no. (%) Borderline Locally advanced Metastatic | 8 (12.7) 16 (25.4) 39 (61.9) |
BMI – no. (%) Underweight Normal Overweight Obesity | 2 (3.1) 34 (54) 21 (33.4) 6 (9.5) |
PS - no. (%) 0 1 2 | 12 (19) 43 (68.3) 8 (12.7) |
CEA – median (range) | 4.8 (0.5 – 381) |
Ca 19.9 – median (range) | 1131 (2 -6627800) |
Conclusions
With an increased number of patients there is still absence of differences of CTC-0 between metastatic and non-metastatic patients as well as no correlation of CTCs with tumor markers at diagnosis. 500 CTCs continues to be a significant cutoff for overall survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Instituto de Investigación Sanitaria Gregorio Marañón.
Funding
SEOM.
Disclosure
L. Ortega Morán: Financial Interests, Advisory Role: Sanofi; Financial Interests, Speaker’s Bureau: Leo Pharma, Sanofi. G. Torres Perez-Solero: Financial Interests, Personal, Advisory Board: Adacap; Financial Interests, Personal, Invited Speaker: Adacap, Ipsen, Amgen, Roche, Merck, Servier; Financial Interests, Personal, Writing Engagement: Sanofi. P. García Alfonso: Financial Interests, Personal, Advisory Board: Amgen. M. Martin Jimenez: Financial Interests, Personal, Advisory Board: AstraZeneca, Lilly, Roche/Genentech, Daiichi Sankyo, Menarini-Stemline; Financial Interests, Personal, Invited Speaker: Pfizer, AstraZeneca, Lilly, Novartis, Roche/Genentech; Financial Interests, Institutional, Research Grant: Novartis, Roche, Puma; Non-Financial Interests, Member of Board of Directors: TRIO; Non-Financial Interests, Leadership Role: Geicam; Non-Financial Interests, Member: ASCO; Non-Financial Interests, Advisory Board: Seom. A.J. Munoz Martin: Financial Interests, Advisory Board: Sanofi, Pfizer, Leo Pharma, Bayer; Financial Interests, Speaker’s Bureau: Rovi. All other authors have declared no conflicts of interest.
Resources from the same session
1579P - Gender differences and worse metastatic survival outcomes in young adult patients with oesophagogastric cancer: 12-year data from a Czech comprehensive cancer center
Presenter: Tomás Sokop
Session: Poster session 22
1580P - Early onset oesophageal adenocarcinoma: A separate biological entity?
Presenter: Dharmesh Valand
Session: Poster session 22
1581P - Total neoadjuvant chemotherapy with FOLFIRINOX regimen in patients with resectable locally advanced gastric and gastroesophageal junction cancer
Presenter: Maria Sedova
Session: Poster session 22
1582P - Gastroesophageal adenocarcinoma in young adults: Retrospective analysis of clinical and molecular features
Presenter: Daniel Acosta Eyzaguirre
Session: Poster session 22
1583P - Intraperitoneal chemotherapy for peritoneal metastases of gastric origin: A systematic review and meta-analysis
Presenter: Niels Guchelaar
Session: Poster session 22
1585P - The impact of platinum-induced peripheral neuropathy (PN) in first-line treatment on PN and efficacy in second-line paclitaxel (PTX)-based chemotherapy for unresectable advanced gastric cancer (AGC): A prospective observational multicenter study - IVY study
Presenter: Yoshiyasu Kono
Session: Poster session 22
1587P - Analysis of survival outcomes according to start timing of adjuvant chemotherapy in patients with gastric cancer: A retrospective nationwide cohort study
Presenter: Tae-Hwan Kim
Session: Poster session 22
1588P - Analysis of risk factors of anastomotic leakage after minimally invasive esophagectomy with circular cervical anastomosis
Presenter: ming lu
Session: Poster session 22